• Our Team
  • North Shore GP Symposium 2018 March
  • Greenlane Multispecialty GP Symposium 2018 February
  • Patient Info
  • GP Info
  • GP Discuss
  • Links
  • Contact
Menu

Cardiology Institute

Unit 109, 119 Apollo Drive, Albany, Auckland
consult@cardiologist.co.nz
P: xxx-xxxx; F xxx-xxxx
Unit 109, 119 Apollo Drive, Albany, Auckland. P: 000-0000. F: 000-0000. consult@cardiologist.co.nz. EDI: cardinst

T 09-980-6363. M 022-672-8255. F 09-929-3248. consult@cardiologist.co.nz. EDI: CARDINST

North Shore - Suite 109, Level 1, 119 Apollo Drive, Albany, Auckland.

Central - GA1-2; 93-95 Ascot Avenue, Greenlane East, Auckland

Cardiology Institute

  • Our Team
  • North Shore GP Symposium 2018 March
  • Greenlane Multispecialty GP Symposium 2018 February
  • Patient Info
  • GP Info
  • GP Discuss
  • Links
  • Contact

Beta-blockers in Hypertension

October 20, 2016 Andrew To

Case

70-year-old asymptomatic man with hypertension but not cardiovascular disease presented for a routine check. His pulse rate was 40bpm.  His son, aged 45, recently had an MI in Australia.

His medications include

-       Doxazosin 8mg OD

-       Metoprolol 95mg CR OD – since 2006

-       Cilazapril 5mg / Hydrochlorothiazide 12.5mg OD

ECG shows sinus bradycardia, with normal PR interval, QRS duration.

Discussion

Without proven cardiovascular disease, in particular, angina and/or heart failure, the role of beta-blockers for hypertension is debatable.  Even though he is asymptomatic from the sinus bradycardia, it would be useful to adjust his medications with less beta-blockade, and introduce calcium channel blocker.

First line agents for hypertension are one of three classes:

-       ACE inhibitors or Angiotensin receptor blockers

-       Thiazides

-       Calcium channel blockers

There may be some advantage of using ACEi/ARB in the young vs. CCB/thiazides in the older population where isolated systolic hypertension is more prevalent.

β-blocker is generally NOT preferred as first line agent. (JNC8) The exceptions are in the settings of post-myocardial infarction, and heart failure.

Drug preference is mainly influenced by co-morbidities and contraindications, rather than a simple age cut-off. 

 

Author: Dr Andrew To

In Drug Treatment Tags hypertension, beta-blocker, calcium channel blocker, ACE inhibitor, angina, coronary artery disease, heart failure
← Patient centered discussion of primary prevention statin therapy Hypertension treatment – how should we choose? →
Summary Block
This is example content. Double-click here and select a page to feature its content. Learn more
Featured
Jun 11, 2012 John Doe Comment
Jun 11, 2012 John Doe Comment
Latest Article
Jun 11, 2012 John Doe Comment
Jun 11, 2012 John Doe Comment
Jun 11, 2012 John Doe Comment
Jun 11, 2012 John Doe Comment

Copyright @2018 Cardiology Institute; All photos copyright @2018 Andrew To